Recent Analysts’ Ratings Changes for TG Therapeutics (TGTX)

A number of research firms have changed their ratings and price targets for TG Therapeutics (NASDAQ: TGTX):

• 8/7/2026 – TG Therapeutics had its price target raised by JPMorgan Chase & Co. from $65.00 to $72.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – TG Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $78.00 price target on the stock.
• 7/29/2026 – TG Therapeutics had its “hold (c+)” rating reaffirmed by Weiss Ratings.
• 7/27/2026 – TG Therapeutics had its price target raised by B. Riley Financial, Inc. from $55.00 to $86.00. They now have a “buy” rating on the stock.
• 7/13/2026 – TG Therapeutics had its price target raised by HC Wainwright from $70.00 to $77.00. They now have a “buy” rating on the stock.
• 7/7/2026 – TG Therapeutics had its price target raised by Bank of America Corporation from $17.00 to $20.00. They now have an “underperform” rating on the stock.
• 7/6/2026 – TG Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $70.00 price target on the stock.
• 6/22/2026 – TG Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $83.00 price target on the stock.

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.